Archit Organosys Ltd

Financial results and approvals

• Unaudited quarterly results for the quarter ended 30 June 2026 approved.
• Limited Review Report from auditors; no material misstatement noted.
• Audit Committee recommendation considered; Board approved.
• Standalone results; no subsidiaries; consolidation not applicable.

Regulatory/compliance updates

• No material Labour Codes impact for quarter ended 30 June 2026.
• Defined benefit obligations recognized for year ended 31 March 2026; no material impact.

Meeting Details

• Date: August 12, 2026; time and location not disclosed.

Key Agenda Items

• Consider and approve unaudited financial results for quarter ended June 30, 2026.

Other Notes

• Trading window closed from July 1, 2026; reopens 48 hours after results become generally available.

Dematerialisation/Rematerialisation status

• Securities received for dematerialisation during quarter ended 30 June 2026 were confirmed to depositories.
• Securities dematerialised have been listed on the stock exchanges where the earlier issued securities are listed.
• Certificates received for dematerialisation were mutilated and cancelled; depository name updated as registered owner within prescribed timelines.

FY26 results

• 📊 Revenue from operations rose to Rs 14,095.25 lakh, up 12.2% year-on-year.
• 📊 Total income increased to Rs 14,383.71 lakh, up 11.8% year-on-year.
• 📊 PBT rose to Rs 1,099.25 lakh, up 45.9% year-on-year.
• 📊 PAT increased to Rs 805.27 lakh, up 59.2% year-on-year.
• 📊 Q4FY26 revenue was Rs 3,649.89 lakh, versus Rs 3,839.81 lakh in Q3FY26.
• 📊 Q4FY26 PAT was Rs 205.23 lakh, versus Rs 242.53 lakh in Q3FY26.
• 📊 Basic and diluted EPS for FY26 were Rs 3.91 each, versus Rs 2.46 last year.
• 📊 Exceptional and extraordinary items were nil for the year.

Costs

• 📊 Material cost was Rs 3,406.75 lakh, up from Rs 3,356.15 lakh last year.
• 📊 Employee benefit expense rose to Rs 737.00 lakh from Rs 710.15 lakh.
• 📊 Finance costs declined to Rs 228.82 lakh from Rs 257.98 lakh.
• 📊 Depreciation and amortisation increased to Rs 601.44 lakh from Rs 594.23 lakh.
• 📊 Other expenses rose to Rs 1,477.79 lakh from Rs 1,354.14 lakh.

Balance sheet and cash

• 📊 Total assets were Rs 12,667.17 lakh at FY26-end, versus Rs 12,291.87 lakh last year.
• 📊 Equity increased to Rs 7,623.27 lakh from Rs 6,920.57 lakh.
• 📊 Borrowings fell to Rs 2,466.38 lakh from Rs 2,695.20 lakh.
• 📊 Trade receivables rose to Rs 2,454.84 lakh from Rs 2,304.79 lakh.
• 📊 Cash and cash equivalents increased to Rs 137.41 lakh from Rs 6.81 lakh.
• 📊 Operating cash flow was Rs 268.46 lakh, versus Rs 1,852.01 lakh last year.
• 📊 Dividend paid during the year was Rs 102.60 lakh.

Operations

• 📊 Inventories declined to Rs 295.05 lakh from Rs 430.18 lakh.
• 📊 Loans on the asset side were Rs 2,927.44 lakh at FY26-end.
• 📊 Current liabilities declined to Rs 4,321.61 lakh from Rs 4,570.17 lakh.
• 📊 Non-current assets increased to Rs 6,575.19 lakh from Rs 6,142.23 lakh.

Dividend and audit

• 📍 Board recommended final dividend of Rs 1 per share, or 10% on face value.
• 📍 Statutory auditors issued an unmodified opinion on the standalone audited results.
• 📍 The company reported only standalone results.

Segment

• 📍 The company operates in a single reportable segment: Chemicals and Organics.

Financial results approved

• Approved standalone audited financial results for quarter and year ended 31 March 2026.
• Approved standalone statement of assets and liabilities and cash flow statement.
• Auditor issued an unmodified opinion on the standalone audited results.

Dividend

• Recommended final dividend of Rs. 1 per equity share, 10% of face value.
• Dividend is subject to shareholder approval at the ensuing AGM.

Auditor and compliance

• Statutory auditors reported no modified opinion or material audit qualification.
• Company noted new labour codes and recognized related defined benefit obligation provision.

Business and segment

• Company reported a single operating segment: Chemicals and Organics.

Meeting Details

• Board meeting scheduled for Saturday, May 16, 2026.

Key Agenda Items

• Approve audited financial results for the quarter and year ended March 31, 2026.

Other Notes

• Trading window closed from April 1, 2026, until 48 hours after results become generally available.